Certain infectious diseases, such as COVID or the flu, evolve constantly, shapeshifting just enough to outmaneuver our immune ...
Pharmaceutical Technology on MSN8h
Recordati to acquire worldwide rights to Sanofi’s antibody EnjaymoRecordati has reached an agreement with Sanofi for acquiring the worldwide rights to Enjaymo, the only approved treatment ...
Recall germinal centers formed in response to a secondary infection generate a second line of defense, rebuffing memory B ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the acquisition of ...
News Medical on MSN4d
Discovery of antibodies that boost complement activation against K. pneumoniaeThe introduction of clustered enhancing mutations led to complement activation by anti-capsule antibodies for both K.
Research at UMC Utrecht has identified 29 novel antibodies against the bacterium Klebsiella pneumoniae, an important cause of ...
Research at UMC Utrecht has identified 29 novel antibodies against the bacterium Klebsiella pneumoniae, an important cause of ...
Research at UMC Utrecht has identified 29 novel antibodies against the bacterium Klebsiella pneumoniae, an important cause of ...
ImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ: IPA), ImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") ...
Elicera Therapeutics describes how CAR T cells armed with neutrophil-activatingprotein can improve cancer therapy by inducing ...
Monash University researchers have developed a new technique to boost the effectiveness of both traditional and mRNA-based ...
Merck completes acquisition of investigational B-cell depletion therapy, CN201 from Curon Biopharma: Rahway, New Jersey Thursday, October 3, 2024, 10:00 Hrs [IST] Merck, known as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback